@wyv_123 You should look into Repath ($amgn) ha- at current net price <$300 per month, no biosimilar risk because it can’t be profitable. This could become a perpetually growing $15B franchise for $amgn . Genius
@internpierre Before financial analysis, we should remember this company was never intended to be public because it was a true crown jewel of the Agnellis - they had to do it to pay down debt.
The company will always be managed with long term view $race
Mega merger in pharma is now in full force.. what companies offer >$10B Atopline (for NT financial accretion) and strong pipeline (for selling the dream)? $BIIB $REGN come to my mind as optimal targets for any large cap pharmas
@AppleHelix Sadly both companies are actually over-earning - as in they both gutted out (particularly $bmy), so not much room to cut for both companies. $azn $bmy
@ContrarianCurse Agreed. Market (or vast majority of market participants) puts significant premium on certainty (aka “i can sleep well at night” premium”.